The global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics.
The Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Segment by Type
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.3 麻豆原创 by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Perspective (2020-2031)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue
3.1.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served
3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted 麻豆原创 Size by Type (2026-2031)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size (2020-2031)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2020-2025)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size (2020-2031)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2020-2025)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size (2020-2031)
9.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.1.5 1ST Biotherapeutics Recent Development
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.2.5 3B Pharmaceuticals Recent Development
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.3.5 3D-Micromac Recent Development
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.4.5 3DMed Recent Development
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.5.5 3D Systems Recent Development
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.6.5 10X Genomics Recent Development
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.7.5 A*STAR Agency for Science Recent Development
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.8.5 Technology and Research Recent Development
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Development
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.10.5 A2A Pharmaceuticals Recent Development
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.11.5 Abbvie Recent Development
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.12.5 AbCellera Recent Development
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.13.5 ABL Bio Recent Development
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.14.5 Abpro Recent Development
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.15.5 Academy of Military Medical Sciences (China) Recent Development
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.16.5 Accellix Recent Development
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.17.5 Accord Healthcare Recent Development
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.18.5 AccuGenomics Recent Development
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.19.5 ACEA Biosciences Recent Development
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.20.5 AC Immune Recent Development
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.21.5 Acoustic MedSystems Recent Development
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.22.5 Adaptimmune Recent Development
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.23.5 Aduro BioTech Recent Development
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.24.5 Advaxis Recent Development
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.25.5 Adventus Ventures Recent Development
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.26.5 Aerolase Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
听
听
*If Applicable.
